Table 2. Compliance with clinical guideline recommendations for CHF patients.
| Management criterion | Patients should have the management N † | Compliance N (%) |
| Chronic heart failure n = 255 | ||
| RAS antagonist | 90 | 87 (97%) |
| Maximized dose | 82 (94%) | |
| Betablockers | 98 | 91 (93%) |
| Maximized dose | 87 (96%) | |
| Exercise program | 195 | 70 (36%) |
| Heart failure education | 226 | 170 (75%) |
| Influenza vaccination | 208 | 170 (82%) |
| Pneumococcal vaccination | 183 | 116 (63%) |
| Atrial fibrillation n = 122 | ||
| Anticoagulation | 79 | 69 (87%) |
| Diabetes mellitus n = 114 | ||
| HbA1c to target | 114 | 92 (81%) |
| Any lipid therapy | 68 | 62 (91%) |
| Lipids to target | 50 (74%) | |
| BP to target | 100 | 91 (91%) |
| Ophthalmology review | 69 | 24 (35%) |
| Podiatry review | 109 | 0 (0%) |
| Ischaemic heart disease n = 147 | ||
| Anti-platelet | 139 | 136 (98%) |
| Any lipid therapy | 94 | 81 (86%) |
| Lipids to target | 69 (73%) | |
| BP to target | 130 | 122 (94%) |
| Smoking intervention | 10 | 9 (90%) |
†
number represents total number of patients with indication and no contraindication for guideline based management.